PARTI OVERVIEW We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements. CORPORATE I...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001104659-26-013044 | EDGAR | 58K words |
| 2025-02-25 | 2024-12-31 | 0001558370-25-001496 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001558370-24-002497 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001558370-23-003181 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001104659-22-037110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-105939 | EDGAR | 35K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010203 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001558370-25-006497 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001558370-24-014340 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-010971 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007072 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018124 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014266 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009133 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016755 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013018 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001410578-22-001377 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-11 | 0001104659-26-013049 | EDGAR | 2K words |
| 2025-11-04 | 0001104659-25-105953 | EDGAR | — |
| 2025-09-25 | 0001104659-25-093144 | EDGAR | — |
| 2025-08-05 | 0001104659-25-073967 | EDGAR | — |
| 2025-06-13 | 0001104659-25-059435 | EDGAR | — |
| 2025-05-09 | 0001104659-25-046845 | EDGAR | — |
| 2025-05-06 | 0001104659-25-044838 | EDGAR | — |
| 2025-02-25 | 0001104659-25-016779 | EDGAR | — |
| 2025-02-06 | 0001104659-25-009813 | EDGAR | — |
| 2024-11-05 | 0001104659-24-114097 | EDGAR | — |
64 total filings indexed. 37 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001875558 |
| Ticker | NVCT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nuvectis.com |
| Listed | 2022-02-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report